Literature DB >> 3491072

Identification of a second mutation in the protein-coding sequence of the Z type alpha 1-antitrypsin gene.

T Nukiwa, K Satoh, M L Brantly, F Ogushi, G A Fells, M Courtney, R G Crystal.   

Abstract

This study reports the entire nucleotide sequence of the protein coding region sequence of the alpha 1-antitrypsin (alpha 1AT) Z gene, a common form of the alpha 1AT gene associated with serum alpha 1AT deficiency. In addition to Glu342 to Lys342 mutation in exon V which has been previously identified by peptide analysis, another point mutation (GTG to GCG in exon III) in the gene sequence predicts a second amino acid substitution (Val213 to Ala213) in the Z protein. This Val213 to Ala213 mutation was confirmed to be a general finding in Z type alpha 1AT gene by evaluating genomic DNA from 40 Z haplotypes using synthetic oligonucleotide gene probes directed toward the mutated exon III sequences in the Z gene. Furthermore, the exon III Val213 to Ala213 mutation eliminates a BstEII restriction endonuclease site in the alpha 1AT Z gene, allowing rapid identification of this Val213 to Ala213 substitution at the genomic DNA level. Surprisingly, when genomic DNA samples from individuals thought to be homozygous for the M1 gene (the most common alpha 1AT normal haplotype) were evaluated with BstEII, 23% of the M1 haplotypes were BstEII site negative, thus identifying a new form of M1 (i.e. M1(Ala213], likely identical to M1 but with an isoelectric focusing "silent" amino acid substitution (Val213 to Ala213). Although the relative importance of the newly identified exon III Val213 to Ala213 mutation to the pathogenesis of the abnormalities associated with the Z gene is not known, it is likely that M1(Ala213) gene represents a common "normal" polymorphism of the alpha 1AT gene that served as an evolutionary intermediate between the M1(Val213) and Z genes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3491072

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Simultaneous phenotyping and quantification of α-1-antitrypsin by liquid chromatography-tandem mass spectrometry.

Authors:  Yuhong Chen; Melissa R Snyder; Yi Zhu; Linda J Tostrud; Linda M Benson; Jerry A Katzmann; H Robert Bergen
Journal:  Clin Chem       Date:  2011-06-02       Impact factor: 8.327

2.  Molecular characterisation of two alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) Null(Newport) (Gly115----Ser) and (Pi) Z Wrexham (Ser-19----Leu).

Authors:  A Graham; N A Kalsheker; F J Bamforth; C R Newton; A F Markham
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

Review 3.  Molecular biology and respiratory disease. 7. The alpha 1 antitrypsin gene and chronic lung disease.

Authors:  N Kalsheker; K Morgan
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

4.  Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase.

Authors:  R C Hubbard; F Ogushi; G A Fells; A M Cantin; S Jallat; M Courtney; R G Crystal
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

5.  Tissue-specific expression of the human alpha 1-antitrypsin gene is controlled by multiple cis-regulatory elements.

Authors:  R F Shen; Y Li; R N Sifers; H Wang; C Hardick; S Y Tsai; S L Woo
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

6.  Characterization of the molecular basis of the alpha 1-antitrypsin F allele.

Authors:  H Okayama; M Brantly; M Holmes; R G Crystal
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

7.  Elastase regulates the synthesis of its inhibitor, alpha 1-proteinase inhibitor, and exaggerates the defect in homozygous PiZZ alpha 1 PI deficiency.

Authors:  D H Perlmutter; J Travis; P I Punsal
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

8.  Diagnosis of alpha 1-antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products.

Authors:  C R Newton; N Kalsheker; A Graham; S Powell; A Gammack; J Riley; A F Markham
Journal:  Nucleic Acids Res       Date:  1988-09-12       Impact factor: 16.971

9.  Synthesis of stress proteins is increased in individuals with homozygous PiZZ alpha 1-antitrypsin deficiency and liver disease.

Authors:  D H Perlmutter; M J Schlesinger; J A Pierce; P I Punsal; A L Schwartz
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

Review 10.  Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.

Authors:  Maria J Chiuchiolo; Ronald G Crystal
Journal:  Ann Am Thorac Soc       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.